Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Bemnifosbuvir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atea Pharma Reveals Q3 2025 Financials & Business Update
    Atea Pharma Reveals Q3 2025 Financials & Business Update

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186782/0/en/Atea-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183594/0/en/Atea-Pharmaceuticals-Presents-New-Data-Supporting-the-Fixed-Dose-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-a-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-I.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162443/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Supporting-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-Infection-at-The.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075940/0/en/Atea-Pharmaceuticals-Announces-Full-Results-from-Phase-2-Study-of-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-HCV-Presented-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    Atea Pharmaceuticals to Host Virtual HCV Panel on May 14, 2025
    Atea Pharmaceuticals to Host Virtual HCV Panel on May 14, 2025

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072229/0/en/Atea-Pharmaceuticals-to-Host-Virtual-HCV-KOL-Panel-on-May-14-2025.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066217/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Showcasing-Potential-Best-in-Class-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share